Researchers Evaluated Neuroblastoma DNA Profiling
A study analyzed cell-free DNA to assess disease burden in pediatric patients with relapsed or refractory neuroblastoma.
Updated on Oct. 5, 2026 in Cancer
Researchers evaluated 5-hydroxymethylcytosine profiling in pediatric patients, using plasma samples collected through the NANT consortium between 2004 and 2015. This approach aimed to develop a minimally invasive method to monitor disease burden in children with relapsed or refractory cancer.
Why it matters
Developing non-invasive monitoring techniques is critical for tracking tumor progression in pediatric cancer patients without requiring repeated, painful procedures. This research tests the viability of cfDNA profiling as a reliable metric for assessing clinical disease burden.
The study utilized 59 individual samples from 38 patients to compare a 450-gene neuroblastoma score against a 5-gene TaqMan Low-Density Array (TLDA) assay. Researchers specifically assessed correlations with clinical metrics like Curie scores and bone marrow involvement.
The players
NANT consortium
This is a collaborative research group that conducts clinical and biological studies to advance treatments for pediatric patients with high-risk neuroblastoma.
The details
The team performed Nano-hmC-Seal sequencing on cfDNA extracted from plasma samples to generate whole-genome 5hmC profiles. By utilizing these molecular markers, investigators sought to correlate laboratory sequencing results with traditional measures of tumor burden in high-risk pediatric populations.
Timeline
Samples were collected from patients enrolled in NANT study protocols between 2004 and 2005.
Additional patient samples were enrolled as part of the NANT 2015-01 study.
The Big Picture
This study follows the standard retrospective review process established by the NANT consortium for evaluating new diagnostic biomarkers in pediatric oncology. The work contributes to the broader effort to refine diagnostic precision for rare, high-risk cancers.
This research focuses on developing less invasive diagnostic tools that could eventually replace or supplement more painful bone marrow biopsies for children. Families and patients should note that this remains a specialized clinical research effort rather than a currently available standard test.
The takeaway
Advancing liquid biopsy technology provides a path toward improving the quality of life for young patients undergoing cancer monitoring. These findings highlight the potential for molecular profiling to offer a more nuanced understanding of disease status than traditional methods.
Further reading
Learn more about the latest innovations in Cancer research on our dedicated health page.
More information
Researchers have made the study dataset and documentation available through the dbGaP portal.
Source note: This article includes information reported by The National Center for Biotechnology Information.
